NCT06040463 (IDEA) is a NA clinical trial of Diabetes Self-Management Training (DSMT) in Diabetes, sponsored by Sinai Health System.

Who is sponsoring NCT06040463?

NCT06040463 is sponsored by Sinai Health System.

What drugs are being tested in NCT06040463?

Interventions in NCT06040463: Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support.

What condition does NCT06040463 study?

NCT06040463 studies Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.

Is NCT06040463 still recruiting?

NCT06040463 is currently status unknown. Last updated 7 December 2023.

Last reviewed 2023-12-07 · How we verify

NCT06040463: IDEA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Diabetes Equity and Advancing Care Study

Status unknown NA Last updated 7 December 2023

What this trial tests

NA trial testing Diabetes Self-Management Training (DSMT) in Diabetes in 270 participants. Status unknown.

Timeline

23 October 2023

Primary endpoint
31 March 2025

31 March 2025

Quick facts

Lead sponsor	Sinai Health System
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	270
Start date	23 October 2023
Primary completion	31 March 2025
Estimated completion	31 March 2025
Sites	1 location across United States

Drugs / interventions tested

Diabetes Self-Management Training (DSMT)
Remote Glucose Monitoring (RGM)
Community Health Worker tailored support

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus — all drugs for Diabetes Mellitus →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Sinai Health System

Who can join

18 and older, any sex, with Diabetes or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized trial is to determine the optimal combination and sequence of three enhancements for a team-based care model for patients living with diabetes in Chicago. The study aim is to determine optimization of intervention components. Participants will be randomly assigned to diabetes self-management training or remote glucose monitoring. After 6 months, participants will be rerandomized to a subsequent study arm (including a CHW support program) depending on a tailoring variable of change in A1c. Researchers will compare the final 6 study arms to see which combination and sequence of enhancements produces the most improvement in A1c.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Improving Diabetes Equity and Advancing Care (IDEA) to optimize team-based care at a safety-net health system for Black and Latine patients living with diabetes: study protocol for a sequential, multiple assignment, randomized trial.
Jacobs J, Labellarte P, Margellos-Anast H, Garcia L, et al · · 2024 · cited 1× · PMID 39049044 · DOI 10.1186/s13063-024-08346-9
Improving Diabetes Equity and Advancing Care (IDEA) to optimize team-based care at a safety-net health system for Black and Latine patients living with diabetes: study protocol for a sequential, multiple assignment, randomized trial
Jacobs J, Labellarte P, Margellos-Anast H, Garcia L, et al · · 2024 · DOI 10.21203/rs.3.rs-3732602/v1

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06040463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinai Health System
Last refreshed: 7 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06040463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing